Drug intelligence / Profile preview

ABBV-2B04

Development stage: Phase 1
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABBV-2B04 is an investigational monoclonal antibody developed by AbbVie for the treatment of COVID-19. It functions as a SARS-CoV-2 spike protein inhibitor, targeting the coronavirus spike glycoprotein to neutralize the virus and prevent infection. The drug has been evaluated in Phase 1 clinical trials for COVID-19 in multiple countries[1][3]. As of now, it remains in early-stage development. ABBV-2B04 has also been studied both alone and in combination with another monoclonal antibody (ABBV-47D11) for potential enhanced efficacy against SARS-CoV-2[3].

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on ABBV-2B04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-2B04.

Explore the full profile